GFAP and COVID-19: There is evidence of reactive astrogliosis in COVID-19, accompanied by a significant increase in the plasma levels of the astrocyte-specific protein, glial fibrillary acidic protein (GFAP), in patients with moderate to severe COVID-19 [60].